KV Begins Shipping Evamist(TM) to W...(alone substudyreported increased risks o...),Health

Date:4/14/2008

alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 6.8 years and 7.1 years, respectively, of treatment with daily oral conjugated estrogens (CE 0.625 mg), relative to placebo. The estrogen plus progestin WHI substudy reported increased risk of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and DVT in postmenopausal women (50 to 79 years of age) during 5.6 years of treatment with daily oral CE 0.625 mg combined with medroxyprogesterone acetate (MPA 2.5 mg), relative to placebo. The Women's Health Initiative Memory Study (WHIMS), a substudy of the WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE 0.625 mg alone and during 4 years of treatment with daily CE 0.625 mg combined with MPA 2.5 mg, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women. In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and MPA and other combinations and dosage forms of estrogens and progestins. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.

In a clinical trial with Evamist(TM), the most common side effects were headache, breast tenderness, nasopharyngitis, nipple pain, back pain, nausea, and arthralgia.

Evamist(TM) should not be used in women with undiagnosed abnormal genital bleeding; known, suspected, or history of breast cancer; known or suspected estrogen-dependent neoplasia; active deep vein thrombosis, pulmonary embolism, or history of these conditions; active or recent arterial thromboembolic disease; liver dysfunction or disease; or known or suspected pregnancy.

Full prescribing information for Evamist
'/>"/>

SOURCE KV Pharmaceutical Company Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6
Related medicine news :

1. When a Mind Begins to Disappear: A Young Familys Journey to the Dark Side
2. Annual National Public Health Week Begins Today
3. Viscorp, Inc. Announces Name Change to Tianyin Pharmaceutical Co Inc. and Begins Trading Under the Ticker OTC BB: TYNP
4. As Congress Begins Debate on Bush Budget, Front-Line Caregivers Urge Rejection of Medicare Cuts
5. XTend Medical (XMDC) Begins Remote Diabetic Telehealth Program
6. High blood pressure worsening in all states for women; begins to stagnate for men
7. Parental Alienation Awareness Organization Begins Preparations for Parental Alienation Awareness Day - April 25th
8. USA TODAY to Report Special Series "Turning 62: The Retirement Boom Begins"
9. Fitness Begins at Home
10. Work Begins on New Regional Hospital Medical Campus
11. Johnson City Medical Center Begins Offering Einstein Bros. Menu Items at Second On Campus Location